Listed

Maze Therapeutics, Inc.

MAZENasdaqCIK 1842295HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$48.0m, Q2 FY2026
Net income−$44.7m, Q2 FY2026
Maze Therapeutics, Inc., income statement, quarterly
Line itemUnitperiod not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30period not labelled2024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reported165Revenue, period not labelled, three months to 2024-06-30$165.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure2.5Revenue, period not labelled, three months to 2024-09-30$2.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure0.0Revenue, period not labelled, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figurenot reportednot reported20.0Revenue, Q1 FY2026, three months to 2026-03-31$20.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344903. Derived: 6-month figure less the 3-month figure.Report this figure
Research and development$m21.9Research and development, period not labelled, three months to 2024-03-31$21.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure19.5Research and development, period not labelled, three months to 2024-06-30$19.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure19.9Research and development, period not labelled, three months to 2024-09-30$19.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure22.2Research and development, period not labelled, three months to 2024-12-31$22.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure27.6Research and development, Q1 FY2025, three months to 2025-03-31$27.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure28.1Research and development, Q2 FY2025, three months to 2025-06-30$28.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure25.2Research and development, Q3 FY2025, three months to 2025-09-30$25.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure27.6Research and development, Q4 FY2025, three months to 2025-12-31$27.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure34.1Research and development, Q1 FY2026, three months to 2026-03-31$34.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure34.9Research and development, Q2 FY2026, three months to 2026-06-30$34.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Operating income$m(28.0)Operating income, period not labelled, three months to 2024-03-31−$28.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure140Operating income, period not labelled, three months to 2024-06-30$139.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure(24.2)Operating income, period not labelled, three months to 2024-09-30−$24.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(29.7)Operating income, period not labelled, three months to 2024-12-31−$29.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure(35.4)Operating income, Q1 FY2025, three months to 2025-03-31−$35.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(36.5)Operating income, Q2 FY2025, three months to 2025-06-30−$36.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure(33.0)Operating income, Q3 FY2025, three months to 2025-09-30−$33.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(38.1)Operating income, Q4 FY2025, three months to 2025-12-31−$38.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure(26.6)Operating income, Q1 FY2026, three months to 2026-03-31−$26.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(48.0)Operating income, Q2 FY2026, three months to 2026-06-30−$48.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.9Interest expense, Q1 FY2026, three months to 2026-03-31$866.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure0.9Interest expense, Q2 FY2026, three months to 2026-06-30$931.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Income tax$mnot reported1.7Income tax, period not labelled, three months to 2024-06-30$1.7m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure(0.3)Income tax, period not labelled, three months to 2024-09-30−$279.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(0.3)Income tax, period not labelled, three months to 2024-12-31−$275.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Net income$m(32.5)Net income, period not labelled, three months to 2024-03-31−$32.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure139Net income, period not labelled, three months to 2024-06-30$139.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(24.8)Net income, period not labelled, three months to 2024-09-30−$24.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(29.6)Net income, period not labelled, three months to 2024-12-31−$29.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure(32.8)Net income, Q1 FY2025, three months to 2025-03-31−$32.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure(33.7)Net income, Q2 FY2025, three months to 2025-06-30−$33.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure(30.1)Net income, Q3 FY2025, three months to 2025-09-30−$30.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(34.6)Net income, Q4 FY2025, three months to 2025-12-31−$34.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure(24.2)Net income, Q1 FY2026, three months to 2026-03-31−$24.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure(44.7)Net income, Q2 FY2026, three months to 2026-06-30−$44.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Diluted EPS$ per share(13.91)Diluted EPS, period not labelled, three months to 2024-03-31−$13.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure3.22Diluted EPS, period not labelled, three months to 2024-06-30$3.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure(10.25)Diluted EPS, period not labelled, three months to 2024-09-30−$10.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figurenot reported(1.15)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(0.77)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure(0.66)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figurenot reported(0.45)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(0.76)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Basic EPS$ per share(13.91)Basic EPS, period not labelled, three months to 2024-03-31−$13.91 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure5.92Basic EPS, period not labelled, three months to 2024-06-30$5.92 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure(10.25)Basic EPS, period not labelled, three months to 2024-09-30−$10.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figurenot reported(1.15)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(0.77)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.77 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure(0.66)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figurenot reported(0.45)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(0.76)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure

Balance sheet

Cash and equivalents$202.6m, Q2 FY2026
Long-term debt$39.0m, Q2 FY2026
Shareholders' equity$453.1m, Q2 FY2026
Maze Therapeutics, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30period not labelled2024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported30.0Cash and equivalents, period not labelled, at 2024-03-31$30.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure175Cash and equivalents, period not labelled, at 2024-06-30$175.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure150Cash and equivalents, period not labelled, at 2024-09-30$149.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure197Cash and equivalents, period not labelled, at 2024-12-31$196.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-25, accession 0001193125-26-122778.Report this figure294Cash and equivalents, Q1 FY2025, at 2025-03-31$294.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure265Cash and equivalents, Q2 FY2025, at 2025-06-30$264.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure317Cash and equivalents, Q3 FY2025, at 2025-09-30$316.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure189Cash and equivalents, FY2025, at 2025-12-31$189.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure199Cash and equivalents, Q1 FY2026, at 2026-03-31$198.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure203Cash and equivalents, Q2 FY2026, at 2026-06-30$202.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Current assets$mnot reportednot reportednot reportednot reported202Current assets, period not labelled, at 2024-12-31$201.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-25, accession 0001193125-26-122778.Report this figure300Current assets, Q1 FY2025, at 2025-03-31$299.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure271Current assets, Q2 FY2025, at 2025-06-30$271.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure391Current assets, Q3 FY2025, at 2025-09-30$391.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure350Current assets, FY2025, at 2025-12-31$349.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure380Current assets, Q1 FY2026, at 2026-03-31$379.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure420Current assets, Q2 FY2026, at 2026-06-30$420.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Total assets$mnot reportednot reportednot reportednot reported241Total assets, period not labelled, at 2024-12-31$240.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-25, accession 0001193125-26-122778.Report this figure333Total assets, Q1 FY2025, at 2025-03-31$332.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure304Total assets, Q2 FY2025, at 2025-06-30$303.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure422Total assets, Q3 FY2025, at 2025-09-30$422.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure397Total assets, FY2025, at 2025-12-31$397.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure420Total assets, Q1 FY2026, at 2026-03-31$419.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure532Total assets, Q2 FY2026, at 2026-06-30$531.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Current liabilities$mnot reportednot reportednot reportednot reported20.7Current liabilities, period not labelled, at 2024-12-31$20.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-25, accession 0001193125-26-122778.Report this figure18.6Current liabilities, Q1 FY2025, at 2025-03-31$18.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure19.9Current liabilities, Q2 FY2025, at 2025-06-30$19.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure22.1Current liabilities, Q3 FY2025, at 2025-09-30$22.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure22.6Current liabilities, FY2025, at 2025-12-31$22.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure21.2Current liabilities, Q1 FY2026, at 2026-03-31$21.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure23.0Current liabilities, Q2 FY2026, at 2026-06-30$23.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Total liabilities$mnot reportednot reportednot reportednot reported43.6Total liabilities, period not labelled, at 2024-12-31$43.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-25, accession 0001193125-26-122778.Report this figure40.8Total liabilities, Q1 FY2025, at 2025-03-31$40.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure41.3Total liabilities, Q2 FY2025, at 2025-06-30$41.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure42.6Total liabilities, Q3 FY2025, at 2025-09-30$42.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure42.2Total liabilities, FY2025, at 2025-12-31$42.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure78.0Total liabilities, Q1 FY2026, at 2026-03-31$78.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure78.5Total liabilities, Q2 FY2026, at 2026-06-30$78.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported38.8Long-term debt, Q1 FY2026, at 2026-03-31$38.8m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure39.0Long-term debt, Q2 FY2026, at 2026-06-30$39.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Current portion of debt, Q1 FY2026, at 2026-03-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure0.0Current portion of debt, Q2 FY2026, at 2026-06-30$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure
Shareholders' equity$m(374)Shareholders' equity, period not labelled, at 2023-12-31−$373.8m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-K filed 2026-03-25, accession 0001193125-26-122778.Report this figure(404)Shareholders' equity, period not labelled, at 2024-03-31−$403.7m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(262)Shareholders' equity, period not labelled, at 2024-06-30−$262.4m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(285)Shareholders' equity, period not labelled, at 2024-09-30−$284.5m. XBRL concept us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure(311)Shareholders' equity, period not labelled, at 2024-12-31−$311.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-25, accession 0001193125-26-122778.Report this figure292Shareholders' equity, Q1 FY2025, at 2025-03-31$292.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure262Shareholders' equity, Q2 FY2025, at 2025-06-30$262.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure379Shareholders' equity, Q3 FY2025, at 2025-09-30$379.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure355Shareholders' equity, FY2025, at 2025-12-31$355.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure342Shareholders' equity, Q1 FY2026, at 2026-03-31$341.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure453Shareholders' equity, Q2 FY2026, at 2026-06-30$453.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure

Cash flow

Operating cash flow−$15.1m, Q2 FY2026
Capital expenditure$107.0k, Q2 FY2026
Maze Therapeutics, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30period not labelled2024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(23.4)Operating cash flow, period not labelled, three months to 2024-03-31−$23.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure145Operating cash flow, period not labelled, three months to 2024-06-30$145.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0000950170-25-107306. Derived: 6-month figure less the 3-month figure.Report this figure(23.2)Operating cash flow, period not labelled, three months to 2024-09-30−$23.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269689. Derived: 9-month figure less the 6-month figure.Report this figure(22.5)Operating cash flow, period not labelled, three months to 2024-12-31−$22.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure(29.5)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$29.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(30.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$30.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344903. Derived: 6-month figure less the 3-month figure.Report this figure(24.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$24.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269689. Derived: 9-month figure less the 6-month figure.Report this figure(27.7)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$27.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure(39.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$39.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure(15.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$15.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344903. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.3Capital expenditure, period not labelled, three months to 2024-03-31$279.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure0.2Capital expenditure, period not labelled, three months to 2024-06-30$160.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0000950170-25-107306. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, period not labelled, three months to 2024-09-30$103.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269689. Derived: 9-month figure less the 6-month figure.Report this figure0.6Capital expenditure, period not labelled, three months to 2024-12-31$605.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2025, three months to 2025-03-31$299.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure0.4Capital expenditure, Q2 FY2025, three months to 2025-06-30$393.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344903. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$68.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269689. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$34.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-25, accession 0001193125-26-122778. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$93.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2026-06-30$107.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344903. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)59.00m, Q2 FY2026
Maze Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares2.3Diluted shares (weighted), period not labelled, three months to 2024-03-312,336,613 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0000950170-25-071375.Report this figure4.3Diluted shares (weighted), period not labelled, three months to 2024-06-304,314,359 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0000950170-25-107306.Report this figure2.4Diluted shares (weighted), period not labelled, three months to 2024-09-302,415,897 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure28.6Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3128,628,430 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure43.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3043,797,421 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure45.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3045,779,577 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269689.Report this figure53.9Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3153,897,216 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219430.Report this figure59.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3058,995,934 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure

Shares outstanding: 55.55mShares outstanding, period not labelled, at 2026-08-0555,549,168 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344903.Report this figure at Aug 5, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.